Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Fluorouracil,FU001,2021,USA,MDV,350,68,45,55,26.5,32,85,12,15,35,30,20,55,25,15,5,20,40,30,18,7,4,9,6,25,60,45,FOLFOX,CAPOX,5-FU/LV,CAPOX,5,3,2,35,70,50,20,50,30,40,2
Fluorouracil,FU002,2022,Canada,Claim Database,420,72,52,48,27.1,28,78,15,12,38,32,18,58,22,14,6,18,42,32,20,8,5,10,7,28,62,48,CAPOX,FOLFOX,CAPOX,5-FU/LV,6,4,3,38,72,52,22,48,30,42,3
Fluorouracil,FU003,2023,UK,MDV,280,65,48,52,25.8,35,88,10,18,32,35,15,60,20,12,8,22,38,35,16,6,3,8,5,22,58,42,FOLFOX,CAPOX,5-FU/LV,CAPOX,4,2,1,32,68,48,18,52,30,38,2.5
